biostudies-literatureHalabi SCancer Research UKNCI NIH HHS64-72https://www.ebi.ac.uk/biostudies/studies/S-EPMC8580377biostudies-literatureUnknown19(3)Biomarkers are needed in patients with non-clear cell renal cell carcinomas (NC-RCC), particularly papillary renal cell carcinoma, in order to inform on initial treatment selection and identify potentially novel targets for therapy. We enrolled 108 patients in ASPEN, an international randomized open-label phase 2 trial of patients with metastatic papillary, chromophobe, or unclassified NC-RCC treated with the mTOR inhibitor everolimus (n=57) or the vascular endothelial growth factor (VEGF) receptor inhibitor sunitinib (n=51), stratified by MSKCC risk and histology. The primary endpoint was overall survival (OS) and secondary efficacy endpoints for this exploratory biomarker analysis were radiographic progression-free survival (rPFS) defined by intention-to-treat using the RECIST 1.1 criterKidney cancer journal : official journal of the Kidney Cancer AssociationTissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial.PMC8580377P30 CA02176525355P30 CA014236George DJJones RJRyan CWStadler WMGarcia JAFoo WCHalabi SKollmannsberger CKZhang SVaishampayan UNEisen TPickering LMCarmack ALogan TFProtheroe AYang QPicus JHainsworth JDArmstrong AJHawkins REPuzanov IfalseTissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial.Biomarkers are needed in patients with non-clear cell renal cell carcinomas (NC-RCC), particularly papillary renal cell carcinoma, in order to inform on initial treatment selection and identify potentially novel targets for therapy. We enrolled 108 patients in ASPEN, an international randomized open-label phase 2 trial of patients with metastatic papillary, chromophobe, or unclassified NC-RCC treated with the mTOR inhibitor everolimus (n=57) or the vascular endothelial growth factor (VEGF) receptor inhibitor sunitinib (n=51), stratified by MSKCC risk and histology. The primary endpoint was overall survival (OS) and secondary efficacy endpoints for this exploratory biomarker analysis were radiographic progression-free survival (rPFS) defined by intention-to-treat using the RECIST 1.1 criter2021-01-01T00:00:00Z2021 Oct2026-05-07T19:38:25.242Z2022-02-11T12:57:42.814ZS-EPMC85803773476507610.52733/kcj19n3-a1